Insmed Inc.
AstraZeneca Exercises Option for Brensocatib Development in COPD and Asthma
Summary
On March 8, 2024, Insmed Incorporated announced that AstraZeneca AB exercised its second and final option under their 2016 License Agreement to further develop and commercialize brensocatib for chronic obstructive pulmonary disease (COPD) or asthma. This advancement permits AstraZeneca to proceed beyond Phase 2b clinical trials and potentially commercialize brensocatib in these indications, subject to reaching satisfactory terms in good faith negotiations with Insmed. Insmed retains full rights for brensocatib in all other indications.
Profitelligence Alerts
Get alerts for INSM
Be first to know when Insmed Inc. files with the SEC.
Filing Categories
Advertisement
About Insmed Inc.
Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.
Official SEC Documents
Advertisement